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Historical developement
Google scholar 4
Wound
• USA       6 million ($25 billion annually)
• Europe        2% of health budgets (1,2)
• Iran        4% of health budgets (3) 
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Wound Healing
• complex biological process
• restoration of tissue integrity.
• four phases:
1.haemostasis,
2.inflammation
3.proliferation , 
4.tissue remodeling(4)
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Wound Healing
Wound Healing
A variety of methods:
• primary intention,
• secondary intention
• tertiary intention, 
• skin grafts, and flaps
• Cell therapy
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Cell Therapy
• Autologous cells
• Simple
• Less time-consuming
• Reduces the surgical burden 
• Not permanently 
• Migration and proliferation of host cells
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Cell Therapy
APPLICATION OF CELLS
• Keratinocytes
• Fibroblasts
• adipose-derived stromal vascular fraction cells
• Platelets
• Stem cell(5)
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Stem cell
Characteristics
• foundation cells for every organ and tissue.
• Throughout our lives
• replace injured tissues, skin, hair, blood every day.
• self-renew
• Differentiate(6)
• Clonogenic(7) 
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Stem cell
wwwResearchgate.net
Source of 
origin
Differentiation 
potential
classification
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Adult
Totipotent
Pluripotent
Multipotent
Unipotent
Stem cell
Classification
www.isscr.org l isscr@isscr.org
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Stem cell
1. Kalra K, Tomar P. Stem cell: basics, classification and applications. American Journal of 
Phytomedicine and Clinical Therapeutics. 2014;2(7):919-30. 13
Stem Cell
14Clinicaltrials.gov, accessed: 28/3/2013)
Stem cell
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Stem Cell
Mesenchymal Stem Cells(Msc)
• Friedenstein in 1966.
spindle-shaped
clonogenic cells in monolayer cultures
colony-forming unit fibroblasts (CFU-Fs)
• Caplan(1991)
first considered as stem cells
Named MSCs
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Mesenchymal stem cells (MSCs) 
• marrow stromal cells
• self-renewing population of multipotent cells.
• to differentiate into diverse mesodermal cell types.
including osteoblasts, chondrocytes and adipocytes
• bone marrow and many other adult tissues.(8)
• in utero MSC transplantation(9)
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Mesenchymal stem cells (MSCs) 
• Most preferred Stem cells  for clinical application
convenient isolation
lack of significant immunogenicity
lack of ethical controversy
potential differentiate(10)
• repair of bone
• Support hematopoiesis
• gene therapy vehicles(11)
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Mesenchymal stem cell
Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nature reviews 
immunology. 2008;8(9):726.
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Mesenchymal Stem cell
• plastic-adherent cells
• lack specific and unique markers
express CD105, CD90 and CD73
lack expression of CD45, CD34, CD14 or CD11b,
CD79alpha or CD19  and HLA-DR surface molecules (7)
• Immunomodulatory capacities(12,8)
• deliver anti-cancer treatments because home to tumour sites
• regenerative wound healing(12)
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Msc in Wound Healing
• key to regenerative wound healing.
• orchestrate wound repair by:
1.structural repair via cellular differentiation
2. immune-modulation
3. secretion of growth factors (neovascularization and repithelialization)
4. mobilization of resident stem cells(homing)(13)
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Msc Homing
Homing Definition
• the delivery of the cells to the site of injury.(14)
• the arrest of MSCs within the vasculature of a tissue followed by 
transmigration across the endothelium(10)
• problem in the field of cell-based therapies.(14)
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Msc Homing
History
• first studies             the origin of the bone marrow MSCs after 
allogeneic bone marrow transplantation 
• MSC transplantations in animal models:
donor-derived non-haematopoietic cells were present
in the bone marrow, thymus, spleen and liver
• Devine et al and Chapel et al:
MSC transplantations in non-human praimtes.
MSCs in a variety of tissues.(0.1% and 2.7%)
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Msc Homing
• Erices et al
• described the homing and 
• survival of human cord blood derived MSCs in the bone marrow of 
immunodeficient (nude) mice after systemic infusion
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Msc Homing
25
Balaji S, Keswani SG, Crombleholme TM. The role of mesenchymal stem cells in the regenerative wound healing 
phenotype. Advances in wound care. 2012;1(4):159-65
Msc Homing
The study of homing, is  complex because:
1. lack of universally accepted criteria
• defining the MSC phenotype 
• their functional properties
2. rare presence of MSCs within blood.
3. diverse methods used to culture MSCs(10)
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Msc Homing
Critical questions
1) host MSCs       ?          peripheral blood
2) exogenous MSCs             ?             ischemic tissues
peripheral blood       ?    Inflammation
3) host MSCs     ?        peripheral blood      ?      target ischemic tissues(10)
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Msc Homing
Karp JM, Teo GSL. Mesenchymal stem cell homing: the devil is in the details. Cell stem cell. 2009;4(3):206-16.
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Msc Homing
Mechanism
• first step: CD44 and selectin
• Second step: The G-protein coupled   receptors activate  chemokine 
receptors.
CXCR4-stromal derived factor-1 (SDF-1)
• third step: Integrins
Integrin 4α +β1          VLA-4 (very late antigen 4) VCAM-1
(vascular cell adhesion molecule 1) (15)      
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Mechanism
30Homing and migration of mesenchymal stromal cells: How to improve the efficacy of cell therapy? Ann De Becker, Ivan 
Van Riet2016
Homing Msc
Mechanism
• final step : MMP-2 and MMP-9
Degrade collagen and  gelatin
Regulating
• MMP-2
• TIMP-3(tissue inhibitor of metalloproteinases 3)
• MT1-MMP(Membrane type 1 MMP)
• ProMMP-2 +   MT1-MMP + TIMP-2             MMP2*
• ProMMP-2 + TIMP-1              MMP2 Inactive          
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Homing Msc
Regulating
1. PDGF(platelet-derived growth factor)
2. HGF(hepatocyte growth factor)
• induce MSC migration.
• gels or scaffolds for improve the in vitro migration(15)
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Homing Msc
Molecules Migration stage References
Adhesion molecules VLA-4, VCAM-1, 
ICAM-1, P-selectin
Rolling and transendothelial
migration
(16-17)
Chemokines/receptors IL-8, MIP-1α, MCP-1, 
SDF-1 ,CCR1/2/4/6/8/9 
CXCR1/2/3/4/5/6
Chemotaxis and traffic 18
Cytokines/growth 
factors
TGF-β, TNF-α, IL-1β, 
IL-6, IL-3, FlT3-L,
IGF-1, SCF, HGF, 
PlGF, PDGF
Chemotaxis and traffic 19
Matrix 
metalloproteinases
MMP-1, MMP-2 Invasion 20
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Msc Homing
multiple factors:         
1.Age, Passage Number, and Dosage of MSCs
passage number              the engraftment efficiency of MSCs     
Age               potency of resident stem/progenitor cell                                                               
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Msc homing
• multiple factors:
2. Source and Culture Conditions of MSCs
• Multiple different tissues          differences in the phenotype 
(challenge)
• International Society for Cellular Therapy (ISCT)
• freshly isolated MSCs home better(    CXCR4 chemokine Receptor)
• matrix metalloproteases (MMPs)(14)
35
Msc Homing
• multiple factors:                                                   Intravenous                                                        
3. Delivery Method               systemic
Intra-arterial
Local                        Intracoronary
direct
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administration                     
Msc Homing
multiple factors:
3. Delivery Method
• IV injection is the most widely used:  
• minimally invasive
• can be readily repeated
• the oxygen and nutrient rich vasculature
• IV injection lungs       target tissues
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Msc Homing 
multiple factors:
3. Delivery Method
• IA compared to IV:
higher risk complication
tissue-specific homing but microthrombi(15)
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Mesenchymal Stem Cells Home to Sites of Injury and Inflammation. Kristine C.2011 39
Msc Homing 
multiple factors:
4. Host Receptability-Injury versus Noninjured
• low immunogenicity
• chemo-attractants 
• genetically engineered
• Vasodilator(14)
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Msc Homing
How Can We Improve The Homing Efficiency Of Mscs?
• only a small proportion of a MSCs remains in the target tissue.
Limited expression of homing molecules on MSCs
lose the expression of homing molecules during in vitro expansion
different expression profile of homing molecules
Approaches
1. Modification of the mode of administration
2. changing culture conditions
3. Genetic modifications
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Msc Homing
Approach
4. Cell surface engineering
5. Modification of the target tissue(14)
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Msc Homing
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Msc Homing
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Msc Homing
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JAM-A promotes wound healing by enhancing both homing and secretory activities of 
mesenchymal stem cell Minjuan Wu∗†,2015
Msc Homing
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JAM-A promotes wound healing by enhancing both homing and secretory activities of mesenchymal stem cell
Minjuan Wu∗†,2015
Future Developement
• Genetic engineering
• current medical and surgical interventions for wound(21)
• Understanding exact mechanism improve future MSC-derived 
therapies(22)
• studies would benefit from a better understanding
of MSC biology.
• A better understanding of MSC homing, allow researchers to optimize 
the migration capacities.(15)
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Abbreviation
• CD: Cluster of differentiation; 
• EC: Endothelial cell
• BM: Basement membrane
• HCELL: Hematopoietic cell E-/L-selectin ligand 
• PSGL-1: P-selectin glycoprotein
• ligand-1; SLEX: Sialyl Lewis X
• SDF-1: Stromal cell derived factor 1
• VLA-4: Very late antigen 4
• VCAM-1: Vascular cell adhesion molecule 1
• Ab: Antibody
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Abbreviation
• TIMP:Tissue inhibitor of metalloproteinases
• MMP: Matrix metalloproteinase; 
• EPO: Erythropoietin
• G-CSF: Granulocyte colony stimulating factor
• MSC: Mesenchymal stromal cell.(15)
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